novo nordisk is cutting prices on its popular glp-1 drugs. cuts of Ozempic, Wegovy, and Rybelsus by up to 50% Trump low-cost GLP-1 plan a

The Journal ofclinical investigation, 127(12), 42174227

This GLP-R1 agonist seems to increase oncogenesis in multiple tissues, including the thyroid, bladder, pancreatic, and colorectal [97, 110, 121]

This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 digital issues and online access to articles $119.00 per year only $9.92 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

This became known as the "incretin effect," which led researchers to hypothesize that some hormones released from the gut were enhancing insulin secretion

This piece in 1993 also provided new insights into the biology of exendin, namely that exendin-4 was a full agonist of the human GLP-1 receptor, which Mojsov argues was crucial to convincing Amylin to develop exendin as a drug for diabetes (see below)

Mounjaro generally outperforms Ozempic in terms of A1C reduction and weight loss